重组人甲状旁腺激素(1-84)对糖尿病活动性Charcot神经骨关节病缓解的影响:随机双盲安慰剂对照研究
本研究为随机双盲安慰剂对照试验,纳入糖尿病急性活动性Charcot足患者,在膝下石膏固定及钙和维生素D3补充基础上,比较全长PTH(1-84)与安慰剂对CN缓解时间和骨折愈合的疗效。主要结局为连续两次每月访视足部皮温差>2°C定义的CN缓解。结果显示PTH(1-84)未显著缩短缓解时间或改善骨折愈合。
要点
- PTH(1-84)未缩短糖尿病活动性Charcot足的中位缓解时间(5个月 vs 6个月,P=0.64)。
- PTH(1-84)未提高12个月内CN缓解的可能性(OR 0.80,95%CI 0.3-2.13,P=0.66)。
- MRI和X线骨折评分在两组间无显著差异。
核心结论
- 在膝下石膏固定和钙/维生素D3补充基础上,每日PTH(1-84)未缩短活动性CN的缓解时间,也未促进骨折愈合。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入糖尿病急性(活动性)Charcot足患者,随机接受全长PTH(1-84)或安慰剂,均联合膝下石膏固定及钙和维生素D3补充。
主要发现
- 中位缓解时间:干预组5个月(95%CI 4, 12),对照组6个月(95%CI 2, 9)。
- 单变量混合Cox和logistic回归显示两组缓解时间无显著差异(P=0.64),缓解可能性亦无显著差异(P=0.66)。
- 缓解风险比0.84(95%CI 0.41, 1.74;P=0.64),12个月内缓解比值比0.80(95%CI 0.3, 2.13;P=0.66)(干预组 vs 对照组)。
- 线性回归分析显示治疗对MRI骨折评分(系数0.13 [95%CI -0.62, 0.88];P=0.73)和足踝X线骨折评分(系数0.30 [95%CI -0.03, 0.63];P=0.07)均无显著影响。
关键数值与推荐
- CN缓解定义为连续两次每月访视足部皮温差>2°C。
- 主要结局为CN缓解时间。
临床怎么用
- 对于糖尿病活动性Charcot足,在标准膝下石膏固定和钙/维生素D3补充基础上,加用PTH(1-84)未显示额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fractures in Charcot neuro-osteoarthropathy (CN) often fail to heal despite prolonged immobilization with below-knee casting. The aim of the study was to assess the efficacy of recombinant human parathyroid hormone (PTH) in reducing time to resolution of CN and healing of fractures. RESEARCH DESIGN AND METHODS: People with diabetes and acute (active) Charcot foot were randomized (double-blind) to either full-length PTH (1-84) or placebo therapy, both in addition to below-knee casting and calcium and vitamin D3 supplementation. The primary outcome was resolution of CN, defined as a skin foot temperature difference >2°C at two consecutive monthly visits. RESULTS: Median time to resolution was 5 months (95% CI 4, 12) in intervention and 6 months (95% CI 2, 9) in control. On univariate mixed Cox and logistic regression, there was no significant difference in time to resolution between the groups (P = 0.64) or in the likelihood of resolution (P = 0.66). The hazard ratio of resolution was 0.84 (95% CI 0.41, 1.74; P = 0.64), and the odds ratio of resolution by 12 months was 0.80 (95% CI 0.3, 2.13; P = 0.66) (intervention vs. control). On linear regression analysis, there were no significant differences in the effect of treatment on fracture scores quantitated on MRI scans (coefficient 0.13 [95% CI -0.62, 0.88]; P = 0.73) and on foot and ankle X-rays (coefficient 0.30 [95% CI -0.03, 0.63]; P = 0.07). CONCLUSIONS: This double-blind placebo-controlled trial did not reduce time to resolution or enhance fracture healing of CN. There was no added benefit of daily intervention with PTH (1-84) to below-knee casting in achieving earlier resolution of CN.
引用
- Petrova NL, Donaldson NK, Bates M, et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2021. PMID: 34088701. doi:10.2337/dc21-0008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。